Novo Nordisk's oral Wegovy pill is now available, and HR and benefits teams are asking the same questions: Will this reduce costs? Will it improve access? Will members finally stop calling about GLP-1 coverage?   At Scripta, we're already seeing what's happening on the ground—and the reality is more complicated than the headlines suggest. Here's what plan sponsors need to understand as this new formulation enters the market. "Oral" Doesn't Mean Lower Cost or Easier Access   T

Cigna’s announcement that Evernorth will move away from traditional manufacturer rebates and toward up-front, net drug pricing reflects a broader industry reckoning: opaque pricing models are no longer sustainable in a healthcare environment under intense cost scrutiny.   For HR and benefits professionals, this shift is welcome. Net pricing promises clearer visibility into drug costs and a more straightforward financial model. But transparency—on its own—does not guarantee be

By Antonio Ciaccia, Co-Founder of 46brooklyn Research and President of 3 Axis Advisors As we close out 2025, it's time to examine what this year revealed about the prescription drug marketplace—and what it means for employers heading into 2026. I recently joined Scripta Insights for a "pharmacy benefits autopsy" to dissect the year's most significant developments. What emerged wasn't just a story about new drugs or evolving regulations, but rather a clear picture of how deepl